The CCL27 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the near-haploid human HAP1 cell line, designed to disrupt CCL27 gene expression. This product provides a loss-of-function model for studying the chemokine CCL27, which mediates skin-homing memory T cell recruitment through the CCR10 receptor. The polyclonal nature offers a heterogeneous gene-edited pool suitable for pooled screens and functional studies.
HAP1 is a near-haploid cell line from KBM-7 chronic myeloid leukemia cells, characterized by a haploid karyotype that simplifies gene knockout. Its adherent, fibroblast-like morphology and compatibility with standard assays make it a versatile platform. Widely used in genetic screens, HAP1 cells enable unambiguous gene-function analysis due to single-allele targeting, reducing genetic redundancy.
CCL27 (cutaneous T cell-attracting chemokine, CTACK) is produced by keratinocytes under regulation by TNF-alpha, IL-1 beta, IFN-gamma, and IL-17. It selectively binds the CCR10 receptor on memory T cells, initiating G-protein coupled signaling cascades. Downstream effectors include PI3K, AKT, ERK1/2, and JAK/STAT pathways, leading to actin polymerization, chemotaxis, and integrin activation. CCL27 interacts with glycosaminoglycans and extracellular matrix components, and its signaling potentiates T-cell migration into the skin, a critical process in cutaneous immune surveillance.
In the HAP1 context, CCL27 knockout allows dissection of its signaling functions in a haploid background, ensuring a null phenotype for clear pathway analysis. This model is valuable for studying chemokine-receptor interactions and intracellular signaling without allelic redundancy, facilitating mechanistic studies of chemokine-mediated migration and adhesion.
These cells support chemotaxis assays, flow cytometry for migration markers, ELISA for chemokine secretion, and Western blot/qPCR for signaling molecules such as AKT, ERK1/2, and STAT. Applications include modeling inflammatory skin diseases like atopic dermatitis and psoriasis, and drug screening for CCL27-CCR10 antagonists. For further information, please contact Ascent Research.
